AMLX Valuation Analysis After Share Price Volatility

요약

“Amylyx Pharmaceuticals stock has declined 4% daily, 22% monthly, but remains up 16% year-to-date and 174% annually.”
“Trading at $13.29, the stock shows a 72% intrinsic discount and 76% discount to analyst targets, with fair value estimated at $22.20.”
“The company's avexitide targets post-bariatric hypoglycemia, an unmet medical need with 160,000 potential U.S. patients.”

Valuation neutral Drawdown neutral Recent recovery

주가 변동성 이후 AMLX 밸류에이션 분석
Amylyx Pharmaceuticals 주가는 일간 4%, 월간 22% 하락했으나 연간 16%, 1년간 174% 상승.
$13.29에서 거래되며 72% 내재적 할인과 76% 분석가 목표가 대비 할인, 공정가치 $22.20로 평가.
회사의 avexitide는 16만 명의 미충족 치료 필요 환자를 대상으로 한다.

출처: simplywall.st
링크: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/a-look-at-amylyx-pharmaceuticals-amlx-valuation-after-recent

소셜 공유 미리보기(OG) 전용 페이지입니다.